Literature DB >> 23982775

Unilateral intravitreal dexamethazone implant for bilateral retinitis pigmentosa-related macular edema.

Mushen Alhassan1, Jean-Claude Quintyn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23982775     DOI： 10.1007/s00417-013-2447-8

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  4 in total

1.  Intravitreal dexamethasone implant (Ozurdex) for macular edema secondary to retinitis pigmentosa.

Authors:  Mayer Srour; Giuseppe Querques; Nicolas Leveziel; Jennyfer Zerbib; Julien Tilleul; Elise Boulanger-Scemama; Eric H Souied
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-12-29       Impact factor: 3.117

2.  Association of antiretinal antibodies and cystoid macular edema in patients with retinitis pigmentosa.

Authors:  J R Heckenlively; B L Jordan; N Aptsiauri
Journal:  Am J Ophthalmol       Date:  1999-05       Impact factor: 5.258

3.  Laboratory evidence of sustained chronic inflammatory reaction in retinitis pigmentosa.

Authors:  Noriko Yoshida; Yasuhiro Ikeda; Shoji Notomi; Keijiro Ishikawa; Yusuke Murakami; Toshio Hisatomi; Hiroshi Enaida; Tatsuro Ishibashi
Journal:  Ophthalmology       Date:  2012-09-15       Impact factor: 12.079

4.  Bilateral intravitreal dexamethasone implant for retinitis pigmentosa-related macular edema.

Authors:  Ali Osman Saatci; Ozlem Barut Selver; Goktug Seymenoglu; Aylin Yaman
Journal:  Case Rep Ophthalmol       Date:  2013-03-25
  4 in total
  2 in total

1.  Short-term outcomes of subtenon triamcinolone acetonide injections in patients with retinitis pigmentosa-associated cystoid macular edema unresponsive to carbonic anhydrase inhibitors.

Authors:  Buğra Karasu
Journal:  Int Ophthalmol       Date:  2019-11-26       Impact factor: 2.031

Review 2.  Retinitis pigmentosa-associated cystoid macular oedema: pathogenesis and avenues of intervention.

Authors:  S Strong; G Liew; M Michaelides
Journal:  Br J Ophthalmol       Date:  2016-12-02       Impact factor: 4.638
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.